Favipiravir: A new and emerging antiviral option in COVID-19.
Favipiravir: A new and emerging antiviral option in COVID-19.
复制标题
DOI：
10.1016/j.mjafi.2020.08.004
复制
发表时间：
2020-10-01
期刊：
影响因子：
--
通讯作者：
Udwadia, Zarir F
中科院分区：
文献类型：
--
作者：
Agrawal, Umang;Raju, Reyma;Udwadia, Zarir F
全球报告的病例超过 1600 万例，直径仅为 125 微米的 SARS-CoV-2 给我们的世界留下了不可磨灭的影响。由于缺乏对抗这种疾病的新药，医学界正在竞相寻找可能有效对抗这种新型冠状病毒的新药物。最近引起广泛关注的药物之一，尤其是在印度，是一种最初设计用于流感的抗病毒药物，称为法匹拉韦。在本文中，我们试图在当前大流行的背景下对该药物进行全面、基于证据的审查，以阐明其在治疗 COVID-19 中的作用。
With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.